Opioids are the most widely prescribed drugs for treatment of moderate to severe pain. They are also the most powerful analgesics for treatment of acute and chronic pain. However, their use is plagued by serious side effects, including abuse and addiction, severe withdrawal, constipation, respiratory depression, and death from overdose.
The CDC reports that over the past ten years mortality rates have declined for all serious medical conditions - except for death from prescription opioid abuse, which has risen dramatically since 1990. More than 2 million Americans are seriously addicted to opioids - and it is a devastating addiction. According to the CDC, "this is a major public health problem that is getting worse, and getting worse rapidly." Phoenix PharmaLabs intends to bring drugs to market that will reverse that trend.
Phoenix PharmaLabs, Inc. (PPL) is a privately held, pre-clinical stage drug development company focusing on the development and commercialization of new non-addictive treatments for pain and new therapies for the treatment of opiate addiction. The company was founded in 2002 with the mission to bring its new class of opioid pain therapies and addiction treatment alternatives to the healthcare community.
PPL has designed a new class of opioid drugs with unique opiate receptor characteristics never before seen. Unlike other opioids such as morphine, oxycodone, hydrocodone, etc. that bind strongly to the mu receptor in the brain and then aggressively agonize that receptor, PPL's drugs have high binding affinity at all three opiate receptors (mu, kappa and delta) and more balanced receptor activity than other opioids. This profile results in the first ever opiate analgesics that appear to be non-addicting and free of all significant dangerous side effects.
Extensive animal testing by prominent scientists at leading institutions has demonstrated that the company's drugs offer robust pain relief (10 to 20 times stronger than morphine) without producing significant euphoria - which is what leads to abuse and addiction. They also demonstrate no dysphoria, no physical dependence, no withdrawal, no death from overdose (even at 350x the analgesic dosage), only moderate respiratory depression at 150x dosage, no constipation at 100x dose, and no other serious side effects. Also, they do not precipitate withdrawal in addicted primates and therefore offer very promising use for addiction therapy. The drugs are orally active and inexpensive to manufacture (using PPL's patented process).
We intend to continue to seek complimentary business and investment relationships, out-license opportunities and/or co-development opportunities with both domestic and overseas partners as we continue to advance our drug candidates through clinical trials.